HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Raises Price Target to $47
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $36 to $47.
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $36 to $47.